Log in

Relevant bibliographies by topics / Sclerodermie en plaques

Contents

Journal articles
Dissertations / Theses
Book chapters

Academic literature on the topic 'Sclerodermie en plaques'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Sclerodermie en plaques.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Sclerodermie en plaques"

1

Srisuttiyakorn, Chutika, and Kobkul Aunhachoke. "Scleroderma with Nodular Scleroderma." Case Reports in Dermatology 8, no. 3 (2016): 303–10. http://dx.doi.org/10.1159/000452324.

Full text

Abstract:

Background: Nodular scleroderma is a rare variant of scleroderma which can occur in connection with systemic sclerosis or morphea. A biopsy from the lesion can demonstrate the scleroderma pattern, i.e., keloid pattern or mixed type. Treatment is challenging, and several treatments modalities have been reported with unsatisfactory results. Main Observations: We present a case of systemic sclerosis in a 50-year-old female who developed nodular scleroderma in the absence of deterioration of the scleroderma condition. Although no additional treatment was given, the lesions remained stable without progression. Conclusions: Although this condition is rare, it has been reported sporadically, and clinicians should be able to recognize this variant in cases of scleroderma presenting with firm nodules or plaques.

APA, Harvard, Vancouver, ISO, and other styles

2

Kassira, Sama, Tarannum Jaleel, Peter Pavlidakey, and Naveed Sami. "Keloidal Scleroderma: Case Report and Review." Case Reports in Dermatological Medicine 2015 (2015): 1–4. http://dx.doi.org/10.1155/2015/635481.

Full text

Abstract:

Objective. We report a rare case of keloidal scleroderma and provide an analysis of similar cases.Results. A 41 year-old woman presented with dark brown, indurated, exophytic nodules over the chest along with smaller hyperpigmented plaques scattered over the abdomen, with concomitant sclerodactyly. The clinical, laboratory, and pathological findings were consistent with a diagnosis of keloidal scleroderma. The patient was treated with methotrexate, resulting in reduced firmness of her plaques and no new lesions. A literature review of previously reported cases was performed using keywords including keloidal morphea, keloidal scleroderma, nodular morphea, and nodular scleroderma. In our review, the majority of patients were African American and female. 91% of cases had nodular lesions with distribution on the trunk. The majority of patients exhibited sclerodactyly and pulmonary involvement was reported in 28%1. The majority of patients were ANA positive (63%) and only 10% demonstrated anti-SCL-70 positivity.Conclusion. Keloidal scleroderma is a rare presentation, which can often be clinically confused with keloid and scar formation. Due to this being a rare variant, our knowledge of treatment options and efficacy is limited. Methotrexate could be considered as an initial treatment option for patients with progressive keloidal scleroderma.

APA, Harvard, Vancouver, ISO, and other styles

3

Rambhia, KinjalD, AtulM Dongre, and UdayS Khopkar. "Sclerodermoid plaques: A riddle of ′H′." Indian Journal of Dermatology, Venereology, and Leprology 81, no. 3 (2015): 327. http://dx.doi.org/10.4103/0378-6323.152748.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Francoeur, Cleve J. "Sclerodermoid Plaques in a Middle-aged Man." Archives of Dermatology 127, no. 10 (1991): 1573. http://dx.doi.org/10.1001/archderm.1991.01680090137020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Skakodub, A. A., N. А. Geppe, O. I. Admakin, et al. "Clinical and X-ray diagnostic criteria for maxillofacial damage in children with juvenile limited scleroderma." Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 65, no. 2 (2020): 71–79. http://dx.doi.org/10.21508/1027-4065-2020-65-2-71-79.

Full text

Abstract:

The objective of our study was to improve the diagnosis of maxillofacial lesions in children with juvenile scleroderma. We performed a dental examination of 41 children from 4 to 17 years old with juvenile scleroderma. Based on the clinical X-ray examination we identified the main diagnostic signs of the maxillofacial damage in children with juvenile scleroderma, including partial hemiatrophy, plaque or linear facial lesions, reduced salivation, atrophic glossitis, plaque spots of mucous tongue atrophy, ischemia or shortening of the sublingual bridle, local recession of the gums of the lower jaw, dystopia and tooth supraposition, disocclusion, delay teething, spontaneous resorption of the permanent teeth roots, one-sided delay in the development of jaw bones. Using this complex of symptoms a dentist at the first visit can pre-diagnose scleroderma, which is especially important for the selection of adequate methods of treatment and prevention.

APA, Harvard, Vancouver, ISO, and other styles

6

Gupta, Vishal, Suman Patra, Mohammad Firdaus Ali, and Gomathy Sethuraman. "Sclerodermoid Hypertrichotic Plaques with Insulin-Dependent Diabetes Mellitus." Pediatric Dermatology 32, no. 5 (2015): 731–32. http://dx.doi.org/10.1111/pde.12574.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Valančienė, Greta, Daiva Jasaitienė, and Skaidra Valiukevičienė. "Pathogenesis and treatment modalities of localized scleroderma." Medicina 46, no. 10 (2010): 649. http://dx.doi.org/10.3390/medicina46100092.

Full text

Abstract:

Localized scleroderma is a chronic inflammatory disease primarily of the dermis and subcutaneous fat that ultimately leads to a scar-like sclerosis of connective tissue. The disorder manifests as various plaques of different shape and size with signs of skin inflammation, sclerosis, and atrophy. This is a relatively rare inflammatory disease characterized by a chronic course, unknown etiology, and insufficiently clear pathogenesis. Many factors may influence its appearance: trauma, genetic factors, disorders of the immune system or hormone metabolism, viral infections, toxic substances or pharmaceutical agents, neurogenic factors, and Borrelia burgdorferi infection. Various therapeutic modalities are being used for the treatment of localized scleroderma. There is no precise treatment scheme for this disease. A majority of patients can be successfully treated with topical pharmaceutical agents and phototherapy, but some of them with progressive, disseminated, and causing disability localized scleroderma are in need of systemic treatment. The aim of this article is not only to dispute about the clinical and morphological characteristics of localized scleroderma, but also to present the newest generalized data about the possible origin, pathogenesis, and treatment modalities of this disease.

APA, Harvard, Vancouver, ISO, and other styles

8

AB, Guerra. "Congenital Morphea: Two Case Reports." Neonatology and Clinical Pediatrics 7, no. 3 (2020): 1–3. http://dx.doi.org/10.24966/ncp-878x/100062.

Full text

Abstract:

Congenital morphea is a rare and underestimated form of localized scleroderma that presents at birth. From the five known subtypes, linear and plaque morphea are the most common and benign forms and are both described in these cases. Extracutaneous manifestations are rare.

APA, Harvard, Vancouver, ISO, and other styles

9

AB, Guerra. "Congenital Morphea: Two Case Reports." Neonatology and Clinical Pediatrics 7, no. 3 (2020): 1–3. http://dx.doi.org/10.24966/ncp-878x/100062.

Full text

Abstract:

Congenital morphea is a rare and underestimated form of localized scleroderma that presents at birth. From the five known subtypes, linear and plaque morphea are the most common and benign forms and are both described in these cases. Extracutaneous manifestations are rare.

APA, Harvard, Vancouver, ISO, and other styles

10

Rencic, Adrienne, Nooshin Ketabchi Brinster, and Carlos H. Nousari. "Keloid Morphea and Nodular Scleroderma: Two Distinct Clinical Variants of Scleroderma?" Journal of Cutaneous Medicine and Surgery 7, no. 1 (2003): 20–24. http://dx.doi.org/10.1177/120347540300700104.

Full text

Abstract:

Background: For nearly a century, the terms “keloid morphea” and “nodular scleroderma” have been used interchangeably without defined clinical or histologic criteria. Objective: To define the conditions “keloid morphea” and “nodular scleroderma” by correlating the clinical and histologic features. Methods: We retrospectively identified six patients with keloidal lesions and nodules from 70 consecutive patients with scleroderma seen in the dermatology clinic. The clinical presentation and histopathological findings were reviewed. Results: Six of 70 patients with scleroderma (45 systemic and 25 morphea) exhibited keloidal or nodular lesions. All these patients had systemic sclerosis. Clinically one patient (case 1) had nodules; five (cases 2–6) had keloids. The nodular lesions had histologic findings consistent with keloid, while the keloidal plaques were variably keloids or morphea histopathologically. There was no correlation between the clinical morphology and the histologic findings, except for cases 5 and 6. These patients were African–American, with a family history of keloids and typical keloids clinically and histologically that developed from sites with normal skin. Conclusion: Keloid morphea and nodular scleroderma are clinical terms that describe keloidal and nodular lesions in patients most commonly with scleroderma. The clinicopathologic association is variable. Based on a review of the English literature and our series of six patients, we identified two clinical variants; (1) keloidal or nodular lesions arising from sclerodermatous skin with histologic findings of keloid or scleroderma, (2) typical keloids clinically and histologically, arising in normal skin in patients with a family history of keloids. Awareness of these entities is important for proper diagnosis of the cutaneous lesions and for recognizing that the cutaneous findings may be a sign of systemic sclerosis.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Sclerodermie en plaques"

1

BATTESTI, PIERRE-ANTOINE. "Le lichen sclereux facial : a propos de trois cas chez des enfants." Angers, 1994. http://www.theses.fr/1994ANGE1068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Sclerodermie en plaques"

1

Zulian, Francesco. "Paediatric scleroderma and related disorders." In Oxford Textbook of Rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0122.

Full text

Abstract:

Juvenile scleroderma syndromes, including the systemic and the localized varieties, represent the third most frequent chronic rheumatic conditions in paediatric rheumatology after juvenile idiopathic arthritis and systemic lupus erythematosus. Juvenile systemic sclerosis (JSSc) has a variety of clinical manifestations, sometimes different from the adult form. Children show a significantly less frequent involvement of all organs, except for arthritis and myositis which are slightly more common than in adults. Indeed, the overall clinical outcome is better. In most JSSc cases with fatal course, the disease progression is rapid due to the early involvement of internal organs. The recently proposed classification for JSSc enables earlier and more definite diagnoses and provides clear criteria to standardize the conduct of clinical trials. Juvenile localized scleroderma (JLS), also known as morphoea, is much more frequent than JSSc. It comprises a group of distinct conditions which involve the skin and subcutaneous tissues. They range from very small plaques of fibrosis involving only the skin, to diseases which may cause significant functional and cosmetic deformity, with a variety of extracutaneous features. Monitoring of JLS includes semiquantitative clinical scoring methods, a computerized skin score, infrared thermography, and high-frequency ultrasound. Treatment varies from topical glucocorticoids, calcipotriene, or phototherapy, as in circumscribed morphoea, to systemic drugs when there is a significant risk for disability, as in linear scleroderma and generalized or pansclerotic morphoea. A recent randomized controlled trial has confirmed the efficacy of methotrexate in these conditions or mycophenolate mofetil in refractory cases.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!